| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/EPI.13212 |
| P698 | PubMed publication ID | 26471380 |
| P50 | author | Christian Brandt | Q43961821 |
| Michael R Sperling | Q62092135 | ||
| P2093 | author name string | John Whitesides | |
| Wei Liang | |||
| Pavel Klein | |||
| Patrick Kwan | |||
| Jimmy Schiemann | |||
| Tracy Stalvey | |||
| P2860 | cites work | Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial | Q33661884 |
| Patterns of treatment response in newly diagnosed epilepsy. | Q35948540 | ||
| Estimation of the burden of active and life-time epilepsy: a meta-analytic approach | Q36135562 | ||
| Newer drugs for focal epilepsy in adults | Q37979169 | ||
| Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. | Q42997736 | ||
| Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity | Q44736849 | ||
| Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial | Q44773924 | ||
| Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study | Q46109122 | ||
| SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy | Q46799583 | ||
| SV2 modulates the size of the readily releasable pool of secretory vesicles | Q47205051 | ||
| Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial | Q48130509 | ||
| Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. | Q51767935 | ||
| Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. | Q51771465 | ||
| Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. | Q54276194 | ||
| The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam | Q24561949 | ||
| Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) | Q24655420 | ||
| Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma | Q27693823 | ||
| Early identification of refractory epilepsy | Q28144133 | ||
| Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. | Q28281249 | ||
| P433 | issue | 12 | |
| P921 | main subject | placebo | Q269829 |
| patient | Q181600 | ||
| P304 | page(s) | 1890-1898 | |
| P577 | publication date | 2015-10-16 | |
| P1433 | published in | Epilepsia | Q5382969 |
| P1476 | title | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures | |
| P478 | volume | 56 |
| Q52608156 | A Review of the New Antiepileptic Drugs for Focal-Onset Seizures in Pediatrics: Role of Extrapolation. |
| Q36332317 | A big data approach to the development of mixed-effects models for seizure count data. |
| Q48093388 | A resurging boom in new drugs for epilepsy and brain disorders. |
| Q49700507 | A review of the pharmacology and clinical efficacy of brivaracetam |
| Q46010938 | Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus. |
| Q93167475 | Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability |
| Q53073031 | Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. |
| Q88747116 | Brivaracetam |
| Q37605300 | Brivaracetam (Briviact): A Novel Adjunctive Therapy for Partial-Onset Seizures |
| Q39794501 | Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures. |
| Q92671823 | Brivaracetam add-on therapy for drug-resistant epilepsy |
| Q28076065 | Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base |
| Q90369461 | Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation |
| Q50183085 | Brivaracetam in the Treatment of Patients with Epilepsy-First Clinical Experiences |
| Q90397660 | Brivaracetam in the treatment of epilepsy: a review of clinical trial data |
| Q38915714 | Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. |
| Q38922348 | Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy |
| Q38844513 | Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures |
| Q91102261 | Brivaracetam: First Canadian Experience in an Intractable Epilepsy Population |
| Q38743281 | Brivaracetam: First Global Approval |
| Q38752407 | Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment |
| Q49253776 | Brivaracetam: a novel antiepileptic drug for focal-onset seizures |
| Q38626838 | Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures |
| Q38600989 | Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam? |
| Q92020107 | Clinical experience with brivaracetam in a series of 46 children |
| Q50075643 | Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment. |
| Q91436159 | Do certain subpopulations of adults with drug-resistant epilepsy respond better to modified ketogenic diet treatments? Evaluation based on prior resective surgery, type of epilepsy, imaging abnormalities, and vagal nerve stimulation |
| Q91745548 | Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland |
| Q99711397 | Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study |
| Q39899497 | Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis |
| Q47937702 | Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis. |
| Q37113376 | Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies |
| Q57926644 | Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany |
| Q50135002 | Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis |
| Q36284727 | Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis |
| Q38652806 | Evaluation of brivaracetam: a new drug to treat epilepsy |
| Q47836472 | Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures. |
| Q38942572 | Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis. |
| Q47575581 | Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users |
| Q90115720 | Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience |
| Q90717695 | Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial |
| Q90329530 | Natural variability in seizure frequency: Implications for trials and placebo |
| Q37693757 | New developments in the management of partial-onset epilepsy: role of brivaracetam |
| Q38904679 | Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide |
| Q48596485 | Pharmacological interactions between brivaracetam and ethanol in healthy males |
| Q47733662 | Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. |
| Q58583545 | Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents |
| Q26776317 | Profile of brivaracetam and its potential in the treatment of epilepsy |
| Q39006241 | Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). |
| Q87612670 | Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated Tablet |
| Q93094357 | Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial |
| Q91307166 | Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial |
| Q47853821 | Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy |
| Q92641106 | Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis |
| Q39707630 | Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures |
| Q28068507 | Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond |
| Q38621010 | The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs |
| Q38614499 | The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy |
| Q96438570 | Time course of drug-related treatment-emergent adverse side effects of brivaracetam |
| Q47782948 | Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment |
| Q39094490 | Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview |
| Q90644435 | Variability in expression of the human MDR1 drug efflux transporter and genetic variation of the ABCB1 gene: implications for drug-resistant epilepsy |
| Q42317849 | Will Brivaracetam Help My Patient? Only Time Will Tell |
| Q30390285 | [Brivaracetam for add-on treatment in focal epilepsy]. |
Search more.